CERT Certara

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara Automates Scientific Workflows with Phoenix® Cloud

New cloud capabilities cut time to create Tables, Figures, and Listings by 50%

RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL Studio lets pharmacokinetic (PK) and pharmacodynamic (PD) scientists create these components with greater speed and collaboration.

Traditional TFL workflows are often hindered by manual processes, fragmented tools, and the challenges of maintaining visual quality and consistency across studies. Phoenix Cloud is designed to accelerate these and related PK workflows through AI and cloud technology.

"The introduction of TFL Studio marks a pivotal moment in our mission to bring advanced, cloud-native solutions to drug discovery and development," said William F. Feehery, Chief Executive Officer.



A complementary module, AI PK Reports, will be released this quarter. AI PK Reports leverages GenAI to turn tables, figures, and listings into draft PK reports, reducing a process that typically takes scientists days to complete down to minutes. AI PK Reports are powered by , Certara’s GenAI software for regulatory and medical writing.

TFL Studio delivers a user-friendly, no-code environment where scientists can:

  • Build TFLs Faster with Reusable Templates: Create, maintain, and apply standardized templates, reducing setup time and ensuring consistency.

  • Generate Dynamic, Editable Outputs: Easily fine-tune TFLs from source data without intermediate preparation, streamlining the editing and review process.

  • Lower Training Burden: Intuitive tools and transparent workflows make it easier for new users to quickly become proficient, fostering broader adoption across teams.

"TFL Studio empowers scientists to create high-quality TFLs up to 50% faster, freeing them from the technical complexities of moving source data, coding, and manual formatting,” said Martin Snyder, President, Certara Data Sciences. “This allows them to focus on science, derive insights more quickly, and ultimately accelerate critical decision-making."

As the inaugural cloud-native module of Phoenix Cloud, TFL Studio sets the stage for future innovations, including the AI PK Reports module described above. It integrates with , providing a single source of truth for PK/PD data, models and visualizations.

TFL Studio is available now as part of the Phoenix Cloud solution. To learn more about TFL Studio and the Phoenix Cloud platform, visit .

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Learn more at

Certara contact:

Sheila Rocchio

Media contact:

Alyssa Horowitz



EN
04/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Certara

 PRESS RELEASE

Certara Automates Scientific Workflows with Phoenix® Cloud

Certara Automates Scientific Workflows with Phoenix® Cloud New cloud capabilities cut time to create Tables, Figures, and Listings by 50% RADNOR, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution. TFLs (Tables, Figures, and Listings) present data on study participants, treatments, and outcomes visually for clear interpretation. They are critical components of regulatory submissions and scientific publications. TFL St...

 PRESS RELEASE

Certara to Participate in Upcoming Investor Conferences

Certara to Participate in Upcoming Investor Conferences RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences: UBS Global Healthcare ConferenceDate and Time: Tuesday, November 11th 2025 at 2:00PM ET Jefferies Global Healthcare Conference in LondonDate and Time: Tuesday, November 18th 2025 at 10:30AM GMT Stephens Annual Investment ConferenceDate and Time: Tuesday, November 18th 2025 at 1:00PM CT Live webcasts for each ...

 PRESS RELEASE

Certara Expands Biosimulation Market with AI-Driven QSP Platform

Certara Expands Biosimulation Market with AI-Driven QSP Platform Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution. QSP has rapidly become a cornerstone of modern drug discovery and development with QSP-based FDA submissions having nearly doubled every 1...

 PRESS RELEASE

Certara Scientists are Among the Topmost Cited Biopharma Researchers

Certara Scientists are Among the Topmost Cited Biopharma Researchers Certara celebrates its 200 published papers and 11 scientists on Stanford/Elsevier top 2% cited researchers list in 2025 RADNOR, Pa., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced its continued influence in pharmaceutical research. With more than 200 papers authored by Certara scientists* this past year and 11 Certara scientists included on the  of the top 2% most cited scientists across the globe, Certara’s powerhouse of scientific k...

 PRESS RELEASE

Certara to Report Third Quarter 2025 Financial Results on November 6th...

Certara to Report Third Quarter 2025 Financial Results on November 6th, 2025 RADNOR, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2025 after the market close on Thursday, November 6th, 2025. Company management will host a conference call to discuss financial results at 5:00PM ET. Investors interested in listening to the conference call are required to . It is recommended to register at least one day in advance. A live and archived webcast of the event...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch